HDAX Therapeutics has raised USD 3.2 million in an oversubscribed seed funding round led by SeedFolio, FACIT, and Toronto Innovation Acceleration Partners (TIAP), with participation from Eos Bioinnovation and Ontario Centre of Innovation, among other investors.
The funds are planned to be directed toward advancing the company's preclinical candidate nomination and the progression of its pipeline programs. In parallel with the funding, CEO of Eos and vice president at TIAP have joined the HDAX board of directors.
HDAX Therapeutics is a biotechnology company developing novel small molecule therapeutics targeting HDAC6 (Histone Deacetylase 6) for neurological, cardiac, and metabolic disorders. The company's proprietary technology uses a unique two-site binding mechanism to create potent and selective HDAC6 inhibitors, addressing key challenges in drug design such as weak binding, poor pharmacokinetics, and off-target toxicities.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.